<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lisinopril: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lisinopril: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lisinopril: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10811" href="/d/html/10811.html" rel="external">see "Lisinopril: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12558" href="/d/html/12558.html" rel="external">see "Lisinopril: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709016"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When pregnancy is detected, discontinue lisinopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F189191"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Prinivil [DSC];</li>
<li>Qbrelis;</li>
<li>Zestril</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867381"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Lisinopril;</li>
<li>Auro-Lisinopril;</li>
<li>Prinivil [DSC];</li>
<li>PRO-Lisinopril-10;</li>
<li>PRO-Lisinopril-20;</li>
<li>PRO-Lisinopril-5;</li>
<li>RAN-Lisinopril;</li>
<li>SANDOZ Lisinopril [DSC];</li>
<li>TEVA-Lisinopril (Type P) [DSC];</li>
<li>TEVA-Lisinopril (Type Z);</li>
<li>Zestril</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F189238"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin-Converting Enzyme (ACE) Inhibitor;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F189196"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Non-ST-elevation acute coronary syndrome (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate in stable patients prior to hospital discharge as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>). Dosing recommendations based on general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 2.5 to 10 mg once daily (depending on initial blood pressure); titrate slowly based on tolerability and response up to 40 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>ST-elevation myocardial infarction:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>In hemodynamically stable patients with large anterior ST-elevation myocardial infarction, consider starting within 24 hours of presentation as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue therapy indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>). Dosing recommendations based on general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily initiated within 24 hours of presentation; titrate slowly up to 10 mg/day or higher as tolerated under close monitoring to avoid hypotension; maximum: 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-7910229','lexi-content-ref-Reeder.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-7910229','lexi-content-ref-Reeder.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>If tolerated<b>, </b>an angiotensin II receptor-neprilysin inhibitor is generally preferred over an angiotensin-converting enzyme inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; increase dose (eg, double but by no more than 10 mg increments) as tolerated every ≥1 to 2 weeks to a target dose of 20 to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). In hospitalized patients, may titrate more rapidly as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed, up to 40 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Among second-line agents for migraine prevention, consider use in patients with comorbid hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22683887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22683887'])">Ref</a></span>). An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 10 mg once daily; may increase dose after 1 week to 20 mg daily based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11141144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11141144'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb3e0e84-695b-4274-ae22-e40f72895c16">Posttransplant erythrocytosis, kidney transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttransplant erythrocytosis, kidney transplant recipients (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients with a hemoglobin concentration &gt;17 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vlahakos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vlahakos.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 or 5 mg once daily; if inadequate response seen within 4 weeks, may titrate up to 40 mg/day based on hemoglobin and blood pressure response; if hemoglobin remains &gt;17 g/dL after an additional 4 weeks, consider additional therapy (eg, phlebotomy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11518790','lexi-content-ref-8938674','lexi-content-ref-8382847','lexi-content-ref-Vlahakos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11518790','lexi-content-ref-8938674','lexi-content-ref-8382847','lexi-content-ref-Vlahakos.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic or nondiabetic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 10 mg once daily depending on baseline BP. Titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 40 mg/day. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990818"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;30 mL/minute: Initial: 2.5 mg once daily (may consider beginning 5 mg once daily in some patients [eg, hypertension]); titrate slowly based on tolerability and response with close monitoring, not to exceed usual maximum dose of up to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Consider alternative therapy; risk of adverse effects or complications (eg, hyperkalemia, kidney failure) are increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). If necessary, begin 2.5 mg once daily; titrate slowly based on tolerability and response with close monitoring, not to exceed usual maximum dose of up to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22845880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22845880'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daily dosing:</i> Initial: 2.5 mg once daily; when scheduled dose falls on a dialysis day, administer post hemodialysis. Titrate slowly based on tolerability and response with close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>), not to exceed usual maximum dose of up to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Three times weekly (post dialysis) dosing (hypertension only): </i>Initial: 10 mg 3 times weekly administered post hemodialysis on dialysis days; titrate slowly based on tolerability and response with close monitoring to a maximum of 40 mg 3 times weekly administered post hemodialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11728957','lexi-content-ref-24398888','lexi-content-ref-27797886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11728957','lexi-content-ref-24398888','lexi-content-ref-27797886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Initial: 2.5 mg once daily; titrate slowly based on tolerability and response with close monitoring, not to exceed usual maximum dose of up to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Alterations in kidney function during treatment: </i></b>Small, transient increases in serum creatinine are likely to occur within 4 weeks following initiation of therapy or an increase in dose. If serum creatinine increases by &gt;30%, review for possible etiologies (eg, acute kidney injury, volume depletion, concomitant medications, renal artery stenosis) before determining if dose reduction or discontinuation of lisinopril therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32998798'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988027"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution, particularly in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F58859588"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Hyperkalemia: Assess for alternative or contributing factors (eg, diet, concomitant medications) of increased potassium before determining if dose reduction or discontinuation of lisinopril therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32998798'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F189197"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 2.5 to 5 mg once daily) and titrate to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518977'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F189217"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12558" href="/d/html/12558.html" rel="external">see "Lisinopril: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Compounded and commercially available oral solutions have multiple concentrations; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: Limited data available: Oral: Initial: 0.07 mg/kg/dose once daily; maximum initial daily dose: 5 mg/<b>day</b>; titrate dose based on response; maximum daily dose: 0.6 mg/kg/<b>day</b> not to exceed 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17137886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17137886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Initial: 0.07 mg/kg/dose once daily; titrate dose based on response; maximum initial daily dose: 5 mg/<b>day</b>; maximum daily dose: 0.61 mg/kg/<b>day</b> not to exceed 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="74bd0984-e708-47c0-8331-4185378f1f11">Proteinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuria (eg, mild IgA nephropathy, focal segmental glomerulosclerosis [FSGS]):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Oral: Initial: 0.1 to 0.2 mg/kg/dose once daily; increase at 1- to 2-week intervals to target dose of 0.4 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21734640','lexi-content-ref-18825420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21734640','lexi-content-ref-18825420'])">Ref</a></span>); maximum dose: 40 mg/<b>day</b>. Dosing based on a prospective study (total patients: n=138; pediatric patients: n=93, age range: 2 to 17 years) in patients with steroid-resistant FSGS comparing mycophenolate to cyclosporine in which most patients received lisinopril (n=118) for protein sparing effects. Lisinopril was initiated at 0.1 mg/kg/dose and increased every 2 weeks to target dose of 0.4 mg/kg/dose (maximum dose: 40 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21734640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21734640'])">Ref</a></span>). In pediatric patients with mild IgA nephropathy (n=40, mean age: 11.4 years; range: 4.4 to 15.4 years), a similar protocol was used, with an initial dose of 0.2 mg/kg/dose increased after 7 days to 0.4 mg/kg/dose (maximum dose: 20 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18825420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18825420'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128469"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51128470"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F54958263"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use may be associated with <b>increased blood urea nitrogen </b>and <b>increased serum creatinine</b>, resulting in oliguria and <b>acute kidney injury</b> (AKI). Increases in serum creatinine are expected and usually stabilize within 20% to 30% of baseline; higher increases may indicate high efferent tone (such as with hypovolemia, congestive heart failure, or renal artery stenosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; inhibits efferent arteriolar vasoconstriction, lowering glomerular filtration pressure, which can lead to a reduction in glomerular filtration rate (GFR). Kidney hypoperfusion from hypotension may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773167','lexi-content-ref-10724055','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773167','lexi-content-ref-10724055','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; increases in serum creatinine generally occur within 2 weeks of initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>). However, more immediate increases may occur in patients with other risk factors for AKI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22754420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22754420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">- Low effective circulating volume (sodium or volume depletion)</p>
<p style="text-indent:-2em;margin-left:8em;">- Congestive heart failure</p>
<p style="text-indent:-2em;margin-left:8em;">- Hypotension or shock</p>
<p style="text-indent:-2em;margin-left:8em;">- Renal artery stenosis</p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose initiation (especially with concomitant diuretic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773167','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773167','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8773167','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8773167','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic and/or nonsteroidal anti-inflammatory drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27490717','lexi-content-ref-31888533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27490717','lexi-content-ref-31888533'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema</b> may occur rarely; edema may manifest in the head and neck (potentially compromising the airway) or the intestine (presenting with abdominal pain). Use is contraindicated in patients with idiopathic or hereditary angioedema or previous angioedema associated with any angiotensin-converting enzyme inhibitors or neprilysin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28994183','lexi-content-ref-28377081','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28994183','lexi-content-ref-28377081','lexi-content-ref-29884969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action (ie, increased bradykinin and Substance P, vascular permeability, and vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-11558759','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-11558759','lexi-content-ref-29884969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur at any time during treatment. Most cases occur within the first week of therapy but may also occur after years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-2840522','lexi-content-ref-9530537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-2840522','lexi-content-ref-9530537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Black patients (estimated 4- to 5-fold higher risk); the mechanism for this is not completely understood but may be related to genetic variants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8689816','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8689816','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-18413488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-18413488'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-15482412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-15482412'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-9218671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-9218671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-29884969'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Seasonal allergies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16043683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16043683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mechanistic target of rapamycin (mTOR) inhibitors (eg, everolimus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28994183','lexi-content-ref-20093343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28994183','lexi-content-ref-20093343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of neprilysin inhibitor (contraindicated)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cough</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A dry, hacking, nonproductive <b>cough</b> that is typically associated with tickling or scratching in the throat may occur with angiotensin converting enzyme inhibitors (ACEI), including lisinopril in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20130570','lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-10644922','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20130570','lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-10644922','lexi-content-ref-8703645'])">Ref</a></span>). Recurrence is likely with rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8862965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8862965'])">Ref</a></span>). Resolution of cough typically occurs 1 to 4 weeks after ACEI discontinuation but may persist for up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Various proposed mechanisms. May be related to the pharmacologic action (ie, increased bradykinin and substance P, resulting in accumulation in the lungs and bronchoconstriction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; within hours to 4 weeks after initiation but can be delayed for up to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Possibly certain genetic variants (some of which may be independent of the bradykinin pathway) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28084903','lexi-content-ref-30672376','lexi-content-ref-32397904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28084903','lexi-content-ref-30672376','lexi-content-ref-32397904'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>(elevated serum potassium) may occur with angiotensin converting enzyme inhibitors (ACEI), including lisinopril.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; inhibits formation of circulating angiotensin II, which leads to efferent arteriole vasodilation and subsequent lowering of GFR, which lowers potassium elimination. Additionally, interferes with generation and release of aldosterone from the adrenal cortex, leading to an impairment of potassium excretion from the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31119681','lexi-content-ref-1855477','lexi-content-ref-15295051','lexi-content-ref-21883995','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31119681','lexi-content-ref-1855477','lexi-content-ref-15295051','lexi-content-ref-21883995','lexi-content-ref-20150448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Disease states associated with hyperkalemia (congestive heart failure, diabetes mellitus, chronic kidney disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications which cause hyperkalemia (ACEI, ARBs, spironolactone, NSAIDs, beta blockers, heparin, tacrolimus, cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute kidney injury (elevated BUN/serum creatinine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium or concurrent use of potassium supplements (including potassium-containing salt substitutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F189158"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (5% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, orthostatic hypotension, syncope (5% to 7%), vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, erythema of skin, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus, hyperkalemia (2% to 6%; incidence varies in literature and may be impacted by comorbidities) (Reardon 1998; Weir 2010; Yusuf 2008), SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal<b>: </b>Constipation, diarrhea, dysgeusia, flatulence, pancreatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, eosinophilia, hemolytic anemia, increased erythrocyte sedimentation rate, leukocytosis, leukopenia, neutropenia, positive ANA titer, pseudolymphoma (cutaneous), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, asthenia, fatigue, paresthesia, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, gout, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, photophobia, vision loss</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (≤2%; transient), increased serum creatinine (≤10%; transient), renal insufficiency (in patients with acute myocardial infarction: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4%; literature suggests incidence may be as high as 20%) (Bangalore 2010; Israili 1992; Yusuf 2008)<span class="lexi-table-link-container"> (<a aria-label="Cough table link" class="lexi-table-link" data-table-id="lexi-content-cough" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cough')">table 1</a>)</span><span class="table-link" style="display:none;">Cough</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cough" frame="border" id="lexi-content-cough" rules="all">
<caption style="text-align:center;">
<b>Lisinopril: Adverse Reaction: Cough</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lisinopril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Psoriasis (White 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Jenks 2016; Jiang 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Schratzlseer 1994), pancytopenia (Schratzlseer 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Singh 2014), fulminant hepatitis (Larrey 1990), hepatocellular hepatitis (Zalawadya 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Vleeming 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, mood changes (including depressive symptoms), visual hallucination (Doane 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Wang 1996)</p></div>
<div class="block coi drugH1Div" id="F189174"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lisinopril, other ACE inhibitors, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Women who are pregnant, intend to become pregnant, or of childbearing potential and not using adequate contraception; breastfeeding; concomitant use with aliskiren, angiotensin receptor blockers (ARBs), or other ACE inhibitors in patients with moderate to severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>), hyperkalemia (&gt;5 mmol/L), or with heart failure who are hypotensive; concomitant use with ARBs or other ACE inhibitors in diabetic patients with end organ damage; pediatric patients &lt;6 years; pediatric patients 6 to 16 years of age with severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="block war drugH1Div" id="F189155"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Patients with kidney impairment are at high risk of developing neutropenia. Patients with both kidney impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with angiotensin-converting enzyme (ACE) inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patients is required especially within the first few weeks of initial dosing and with dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Avoid use in hemodynamically unstable patients after acute myocardial infarction (MI).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Biggins 2021]; AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs. In a retrospective cohort study of patients ≥65 years of age with MI and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, including patients with serum creatinine concentrations &gt;3 mg/dL (265 micromol/L) (Frances 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant kidney impairment; may be at increased risk for hematologic toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; consider baseline LFTs prior to initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in preexisting kidney insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation, which may lead to further kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Oral solution: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/Ethnicity: In Black patients, the BP-lowering effects of ACE inhibitors may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p></div>
<div class="block foc drugH1Div" id="F189166"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qbrelis: 1 mg/mL (150 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prinivil: 5 mg [DSC], 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prinivil: 20 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zestril: 2.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zestril: 5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zestril: 10 mg, 20 mg, 30 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F189151"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F189176"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Qbrelis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $5.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lisinopril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.01 - $0.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.02 - $0.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.01 - $1.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.02 - $1.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.04 - $1.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.04 - $1.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zestril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $15.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $15.95</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867382"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prinivil: 10 mg [DSC], 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zestril: 5 mg, 10 mg, 20 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F189170"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer as a single daily dose and without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52613168"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p></div>
<div class="block use drugH1Div" id="F189169"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b> Adjunctive therapy to reduce signs and symptoms of systolic heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension in adult and pediatric patients ≥6 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>ST-elevation myocardial infarction:</b> Treatment of acute MI within 24 hours in hemodynamically stable patients to improve survival.</p></div>
<div class="block off-label drugH1Div" id="F44524334"><span class="drugH1">Use: Off-Label: Adult</span><p>Migraine, prevention; Non-ST-elevation acute coronary syndrome; Posttransplant erythrocytosis, kidney transplant recipients; Proteinuric chronic kidney disease, diabetic or nondiabetic; Stable coronary artery disease</p></div>
<div class="block mst drugH1Div" id="F189246"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lisinopril may be confused with fosinopril, Lioresal, Lipitor, RisperDAL</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prinivil may be confused with Plendil, Pravachol, Prevacid, PriLOSEC, Proventil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zestril may be confused with Desyrel, Restoril, Vistaril, Zegerid, Zerit, Zetia, Zostrix, ZyPREXA</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acepril [Malaysia] may be confused with Accupril which is a brand name for quinapril [US]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acepril: Brand name for lisinopril [Malaysia], but also the brand name for captopril [Great Britain]; enalapril [Hungary, Switzerland] </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51891780"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F189160"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alteplase: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Alteplase. Specifically, the risk for angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Green Tea: May decrease the serum concentration of Lisinopril.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme (ACE) inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor for increased concentrations/toxic effects of lithium if an ACE inhibitor is initiated/dose increased, or if switching between ACE inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May increase the serum concentration of Lisinopril.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Racecadotril: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus Products: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: May interact via an unknown mechanism with Angiotensin-Converting Enzyme Inhibitors. Management: Avoid concomitant use of urapidil and angiotensin-converting enzyme (ACE) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307992"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Avoid use of angiotensin-converting enzyme (ACE) inhibitor therapy in patients who may become pregnant and who are not using effective contraception (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Angiotensin-converting enzyme (ACE) inhibitors are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ACE inhibitor is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When ACE inhibitors are used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2023; Fakhouri 2023).</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure in patients planning to become pregnant (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Lisinopril may be effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]). When lisinopril is used for migraine prevention, treatment should be discontinued prior to attempting to conceive (ACOG 2022).</p></div>
<div class="block pri drugH1Div" id="F189177"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lisinopril crosses the placenta (Bhatt-Mehta 1993; Filler 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin-converting enzyme (ACE) inhibitor during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ACE inhibitor use during pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ACE inhibitor in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, pre-eclampsia, delivery complications, stroke and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Discontinue ACE inhibitors as soon as possible once pregnancy is detected. Agents other than ACE inhibitors are recommended for the treatment of chronic hypertension during pregnancy (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]). Consider the use of ACE inhibitors only for pregnant patients with hypertension refractory to other medications (ACOG 2019). Closely monitor pregnant patients on ACE inhibitors with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure or proteinuric chronic kidney disease during pregnancy (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]; Fakhouri 2023).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). Lisinopril is not recommended for migraine prevention during pregnancy (ACOG 2022).</p></div>
<div class="block brc drugH1Div" id="F6198846"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lisinopril is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue lisinopril.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, preventive treatment for migraine in lactating patients should be avoided. When needed, therapy should be individualized considering the available safety data and needs of the patient (AHS [Ailani 2021]). When postpartum treatment with an ACE inhibitor is needed, consider use of an agent other than lisinopril (ESC [Cífková 2020]). Avoid breastfeeding if high maternal doses of an ACE inhibitor are needed (ACOG 2019).</p></div>
<div class="block dic drugH1Div" id="F3339783"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Use potassium-containing salt substitutes cautiously in patients with diabetes, patients with kidney impairment, or those maintained on potassium supplements or potassium-sparing diuretics.</p></div>
<div class="block mop drugH1Div" id="F189164"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; BUN; serum creatinine; electrolytes (eg, potassium [especially in patients on concomitant potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts]); consider baseline LFTs (if preexisting hepatic impairment); monitor for jaundice or signs of hepatic failure; if patient has collagen vascular disease and/or kidney impairment, periodically monitor CBC with differential. If angioedema is suspected, assess risk of airway obstruction (eg, involvement of tongue, glottis, larynx, and/or history of airway surgery).</p></div>
<div class="block pha drugH1Div" id="F189154"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure</p></div>
<div class="block phk drugH1Div" id="F189173"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 hour; Peak effect: Hypotensive: Oral: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 15 years: 20% to 36% (Hogg 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 16 years: ~28%</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~25% (range: 6% to 60%); decreased to 16% with NYHA Class II-IV heart failure</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients 6 months to 15 years: Median (range): 5 to 6 hours (Hogg 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51153969"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Decreased elimination when glomerular filtration rate is &lt;30 mL/minute. With greater impairment, peak and trough lisinopril levels increase, time to peak concentration increases, and time to attain steady state is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F189179"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Hiace | Linopril | Lisino | Lisotec | Neopril | Omace | Zestril</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Doxapril | Lisinal | Prinivil | Sedotensil | Tensopril | Tersif | Tersif md | Zestril</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Acemin | Acetan | Lisihexal | Lisinopril 1a pharma gmbh | Lisinopril actavis | Lisinopril arcana | Lisinopril genericon | Lisinopril interparm | Lisinopril Pfizer | Lisinopril ratiopharm | Lisinopril sandoz | Lisinostad | Lisinotyrol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo lisinopril | Auro lisinopril | Chem mart Lisinopril | Cm lisinopril | Fibsol | Liprace | Lisinobell | Lisinopril an | Lisinopril Drla | Lisinopril Ga | Lisinopril Generic Health | Lisinopril hexal | Lisinopril PS | Lisinopril ranbaxy | Lisinopril sandoz | Lisinopril Winthrop | Lisinopril-bc | Lisodur | Prinivil | Tw lisinopril | Zestril | Zinopril</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Ecopril | Fastril | Fisopril | Linoril | Lipril | Lisopril | Neopril | Nop | Stril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doclisinopril | Lisijenson | Lisinopri EG | Lisinopril bexal | Lisinopril eurogenerics | Lisinopril merck-generics | Lisinopril Pfizer | Lisinopril ratiopharm | Lisinopril sandoz | Lisinopril teva generics belgium | Novatec | Zestril</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Lisinorm | Lizopril | Stripril</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cordacare | Diroton | Linipril | Lisigamma | Lizopril | Prinivil | Skopryl | Vitopril</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lisinovil | Lisopril | Listril | Lonipril | Prilcor | Prinivil | Prinopril | Vasojet | Zestril | Zinopril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril 1 A Pharma | Lisinopril Actavis | Lisinopril Axapharm | Lisinopril Helvepharm | Lisinopril mepha | Lisinopril spirig | Lisinopril Streuli | Lisinopril zentiva | Lisitril | Prinil | Tobicor | Zestril</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lisnop | Lisoril | Lizopril | Stripril | Zestril</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acerdil | Lipreren | Presokin | Tonotensil | Zestril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Jie ci rui | Jin jie tuo | Listril | Wei Yi Luo | Zestril</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acerdil | Linopril | Lisipril | Prinivil | Tensyn</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Diroton | Lisigamma | Lisinopril +pharma | Lisipril | Listril | Prinivil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aceday | Acerbon | Coric | Lisi | Lisi lich | Lisi-puren | Lisibeta | Lisidigal | Lisidoc | Lisigamma | Lisihexal | Lisinopril actavis | Lisinopril al | Lisinopril Atid | Lisinopril aurobindo | Lisinopril biochemie | Lisinopril Corax | Lisinopril CT | Lisinopril Heumann | Lisinopril holsten | Lisinopril puren | Lisinopril ratiopharm | Lisinopril sandoz | Lisinopril stada | Lisinopril teva | Lisodura | Zestril</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril Alpharma | Lisinopril biochemie | Lisinopril stada</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Asteril | Buspin | Cardionil | Carsipril | Cirpril | Ecadol | Ecardil | Eupril | Lipril | Lisichem | Lisinocor | Lisinofran | Lisinopril Lam | Lisiprex | Lisipril | Lisitrol | Lisprino | Lowpril | Presiten | Prinivil | Sinopril | Tensikey | Tensolisin | Zestril</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acerdil | Eucor | Rowenopril | Tensiopril | Tensyn</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Diroton | Lisinopril actavis | Lisinopril stada | Lizinoprils | Prinivil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Linopril | Lisopril | Maxipril | Sinopril | Zestril</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Doneka | Iricil | Lisinopril Acost | Lisinopril aurovitas | Lisinopril bayvit | Lisinopril bexal | Lisinopril cinfa | Lisinopril combino | Lisinopril farmasierra | Lisinopril Merck | Lisinopril normon | Lisinopril pharmacia | Lisinopril ratiopharm | Lisinopril secubar | Lisinopril tamarang | Lisinopril UR | Prinivil | Tensikey | Zestril</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Lipril | Lisipril | Zestril</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cardiostad | Lisinopril actavis | Lisinopril alpharm | Lisinopril generic | Lisinopril generics | Lisinopril merck nm | Lisinopril orion | Lisinopril pliva | Lisinopril ranbaxy | Lisinopril ratiopharm | Lisinopril sandoz | Lisipril | Vivatec | Zestril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril Actavis | Lisinopril Almus | Lisinopril Arrow | Lisinopril Biogaran | Lisinopril eg | Lisinopril g gam | Lisinopril Merck | Lisinopril Pfizer | Lisinopril Qualimed | Lisinopril ratiopharm | Lisinopril rpg | Lisinopril sandoz | Lisinopril teva | Lisinopril Zydus | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril Almus | Lisinopril Arrow | Lisinopril cox | Lisinopril kent | Lisinopril Lupin | Lisinopril sandoz | Zestril</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Lisinova | O pril | Umelis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adicanil | Axelvin | Gnostoval | Icoran | Landolaxin | Leruze | Lisinospes | Lisodinol | Mealis | Nafordyl | Perenal | Press-12 | Pressuril | Prinivil | Terolinal | Thriusedon | Tivirlon | Vercol | Veroxil | Z-bec | Zestril</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo lisinopril | Bf Lisinopril | Cipril | Dapril | Lisopril | Lisoril 10 | Perenal | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Amicor | Irumed | Laaven | Lizinopril | Lizinopril farmal | Lizinopril Genera | Lizinopril Lek | Lizinopril Sandoz | Optimon | Prinivil | Skopryl | Vitopril</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Conpres | Linipril | Lisdene | Lisinopril hexal | Lisinopril ratiopharm | Lisopress | Press 12 | Prinivil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Inhitril | Interpril | Linoxal | Noperten | Nopril | Odace | Tensiphar | Zestril</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bellisin | Carace | Lestace | Lisopress | Lispril | Zesger | Zestan | Zestril</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tensopril</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acinopril | Biolis | Biopril | Cipril | Dilace | Dilis | Hipril | Hypernil | Ilis | Inras | L-pril | L.p.l | Lapril | Linopril | Linoril | Lipril | Lis-ten | Lisace | Lisicard | Lisinace | Lisitec | Lislo | Lisnop | Lisod | Lisonol | Lisoril | Lisotec | Lispres | Listril | Lisupril | Nivant | Normopril | Odace | Prevace | Zestril | Zonapril</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alapril | Lisinopril actavis | Lisinopril aurobindo | Lisinopril Awp | Lisinopril Doc | Lisinopril Doc Generici | Lisinopril eg | Lisinopril fg | Lisinopril Ipso pharma | Lisinopril Merck | Lisinopril Pensa | Lisinopril pmg | Lisinopril sandoz | Lisinopril Winthrop | Nosilix | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Inopril | Linopril | Lisocard | Lisopril | Skopryl | Zestril</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asrarn | Lisinomerck | Lisitril | Lokopool | Longeril | Longes | Railtock</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Auroliza | Lipril | Lisace | Listril | Zestril</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jestril | Lisihexal | Nanopril | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zestril</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tensikey | Zestril</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Diroton | Lisinopril actavis | Lizinoprils | Prinivil | Sinopril</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Doclisinopril | Novatec | Zestril</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acerbon | Dapril | Diroton | Lisigamma | Lizinoprils -grindeks | Prinivil | Tensikey</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alfaken | Dosteril | Fersivag | Kesipril | Lisinopril kener | Lisinopril landsteiner | Litiwen | Ofulid | Pesatril | Presiten | Prinigen | Priniser | Prinivil | Tonogard | Trionipril | Zestril</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Apo lisinopril | Lisdene | Prinivil | Ranopril | Zestril</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cardestril | Deno lisinopril | Eden | Eden lisinopril | Emekpril | Emzipril | Gapril | Greatlight lisinopril | Kuinopril | Linvaspril | Lisikris | Lisinopril | Lisinopril makinga | Lisinopril sandoz | Lisinosyn | Lisiofil | Lizopril | Marley lisinopril | Milton lisinopril | Pemapril | Pharmamax lisinopril | Pocco lisinopril | Presovax | Prilas | Prinpil | Ranopril | Ritepril | Rotapril | Rumapril | Salpril | Shinfield lisinopril | Sinopril | Sivolisinopril | Topix lisinopril | Vispril | Vpl lisinopril | Zisty</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril Accord | Lisinopril Alpharma | Lisinopril aurobindo | Lisinopril CF | Lisinopril Focus | Lisinopril Gf | Lisinopril Merck | Lisinopril ratiopharm | Lisinopril sandoz | Novatec | Zestril</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril sandoz | Vivatec | Zestril</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow Lisinopril | Ethics Lisinopril | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omace</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acerdil | Hipopres | Hipril | Lisilet | Rivasmin lisil | Zestril</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Listril | Priska | Zestril</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bpmed | Conpril | Corace | Lace | Lame | Liface | Lisin | Lisna | Lisopril | Lispril | Lotide | Novatec | Sinopril | Tesipril | Trupril | Veskor | Zairl | Zestril | Ziscar | Zonapril</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diroton | Ikapril | Lisdene | Lisihexal | Lisinopril genoptim | Lisinopril Pfizer | Lisinoratio | Lisiprol | Prinivil | Ranopril</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Prinivil | Qbrelis | Zestril</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ecapril | Farpresse | Lipril | Lisinopril aurobindo | Lisinopril Azevedos | Lisinopril Cinfa | Lisinopril Mylan | Lisinopril ratiopharm | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acerdil | Hipopres | Nisirol | Tonotensil | Zestril</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Glopril | Linopril | Lisino | Lispril | Omace | Zestril | Zinopril</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lipril | Lisigamma | Lisinopril atb | Lisinopril sandoz | Lisiren | Listril | Ranolip | Tonolysin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Diropress | Diroton | Irumed | Lisacard | Lisigamma | Lisinopril | Lisinopril akrikhin | Lisinopril canon | Lisinopril grindex | Lisinopril hexal | Lisinopril krka | Lisinopril obl | Lisinopril Organika | Lisinopril stada | Lisinoton | Lisiprex | Lisoril | Listril | Liten | Lysigamma | Lysinopril | Lysonorm | Lysoryl | Rilace sanovel | Sinopril | Zonixem</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo lisinopril | Linopril | Lisino | Lisoril | Omace | Zestril | Zinopril | Zoril</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lisinopril 2care4 | Lisinopril actavis | Lisinopril arrow | Lisinopril ebb | Lisinopril Mylan | Lisinopril Orifarm | Lisinopril ranbaxy | Lisinopril ratiopharm | Lisinopril stada | Zestril</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Hypersil | Lisdene | Lisoril | Noperten | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Irumed | Lizinopril Galex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dapril | Diroton | Irumed | Lisinopril +pharma</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hipril | Lisdene | Lispril | Prinivil | Zestril</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acerilin | Inhibril | Rilace | Sinopryl | Unopril | Zestril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Genopril | Noprisil | Prinivil | Safepril | Vastril | Zestril</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aurolisa | Dapril | Diroton | Linotor | Lipril | Lisi sandoz | Lisinocol | Lisinopril | Lisinopril apo | Lisinopril grindex | Lisinopril lugal | Lisinopril ratiopharm | Lisinopril teva | Lisinoprilum | Lisinovel | Lisoril | Lizopril | Lopril | Sinopril | Skopryl | Zonixem</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Listril | Sinopril | Zestril</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aklis | Brintenal | Lisibloc | Lisimax | Lisinal | Nisirol | Zestril</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lipresan | Lisilet | Prinivil | Rantex | Tonoten</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agimlisin | Lizetric</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco Zetomax | Austell-Lisinopril | Austell-lisinopril | Cipla lisinopril | Hexal-lisinopril | Liso | Lizro | Lysin | Prilosin | Prinivil | Renotens | Simayla lisinopril | Sinopren | Zemax | Zestril | Zetomax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cipril | Hexal lisinopril | Lisoril | Listril | Odace | Zestril</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Listril | Zestril</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28767167">
<a name="28767167"></a>Alharbi FF, Kholod AAV, Souverein PC, et al. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundam Clin Pharmacol</i>. 2017;31(6):676-684. doi:10.1111/fcp.12313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/28767167/pubmed" id="28767167" target="_blank">28767167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31226134">
<a name="31226134"></a>Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study. <i>PLoS One</i>. 2019;14(6):e0218739. doi:10.1371/journal.pone.0218739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31226134/pubmed" id="31226134" target="_blank">31226134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11728957">
<a name="11728957"></a>Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. <i>Am J Kidney Dis</i>. 2001;38(6):1245-1250. doi:10.1053/ajkd.2001.29221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11728957/pubmed" id="11728957" target="_blank">11728957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24398888">
<a name="24398888"></a>Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. <i>Nephrol Dial Transplant</i>. 2014;29(3):672-681. doi:10.1093/ndt/gft515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/24398888/pubmed" id="24398888" target="_blank">24398888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8773167">
<a name="8773167"></a>Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. <i>Ann Pharmacother</i>. 1996;30(1):55-61. doi:10.1177/106002809603000110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8773167/pubmed" id="8773167" target="_blank">8773167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964864">
<a name="34964864"></a>American Diabetes Association (ADA) Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. Management of diabetes in pregnancy: standards of medical care in diabetes–2022. <i>Diabetes Care</i>. 2022;45(suppl 1):S232-S243. doi:10.2337/dc22-S015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/34964864/pubmed" id="34964864" target="_blank">34964864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S280. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed April 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. doi:10.1001/archinternmed.2010.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [published corrections appear in <i>Circulation</i>. 2011;123(21):e616; <i>Circulation</i>. 2011;124(5):e175; <i>Circulation</i>. 2016;133(24):e715]. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20130570">
<a name="20130570"></a>Baker-Smith CM, Benjamin DK Jr, Califf RM, et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. <i>Clin Pharmacol Ther</i>. 2010;87(6):668-671. doi:10.1038/clpt.2009.231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20130570/pubmed" id="20130570" target="_blank">20130570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693. doi:10.1001/archinte.160.5.685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377081">
<a name="28377081"></a>Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):744-749. doi:10.1016/j.jaip.2017.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/28377081/pubmed" id="28377081" target="_blank">28377081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21035591">
<a name="21035591"></a>Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. <i>Am J Med</i>. 2010;123(11):1016-1030. doi:10.1016/j.amjmed.2010.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/21035591/pubmed" id="21035591" target="_blank">21035591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27926639">
<a name="27926639"></a>Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. <i>Obstet Gynecol</i>. 2017;129(1):174-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/27926639/pubmed" id="27926639" target="_blank">27926639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338866">
<a name="27338866"></a>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2016;18(9):1096-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/27338866/pubmed" id="27338866" target="_blank">27338866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25058867">
<a name="25058867"></a>Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. <i>Am J Med</i>. 2015;128(2):120-125. doi:10.1016/j.amjmed.2014.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25058867/pubmed" id="25058867" target="_blank">25058867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8247923">
<a name="8247923"></a>Bhatt-Mehta V, Deluga KS. Fetal exposure to lisinopril: neonatal manifestations and management. <i>Pharmacotherapy</i>. 1993;13(5):515-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8247923/pubmed" id="8247923" target="_blank">8247923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31119681">
<a name="31119681"></a>Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>J Nephrol</i>. 2019;32(4):499-516. doi:10.1007/s40620-019-00617-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31119681/pubmed" id="31119681" target="_blank">31119681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8689816">
<a name="8689816"></a>Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. <i>Clin Pharmacol Ther</i>. 1996;60(1):8-13. doi:10.1016/S0009-9236(96)90161-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8689816/pubmed" id="8689816" target="_blank">8689816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9218671">
<a name="9218671"></a>Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. <i>JAMA</i>. 1997;278(3):232-233. doi:10.1001/jama.278.3.232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/9218671/pubmed" id="9218671" target="_blank">9218671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28994183">
<a name="28994183"></a>Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. <i>J Clin Hypertens (Greenwich)</i>. 2017;19(12):1377-1382. doi:10.1111/jch.13097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/28994183/pubmed" id="28994183" target="_blank">28994183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDA.1">
<a name="CDA.1"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada," <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11558759">
<a name="11558759"></a>Chiu AG, Newkirk KA, Davidson BJ, Burningham AR, Krowiak EJ, Deeb ZE. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. <i>Ann Otol Rhinol Laryngol</i>. 2001;110(9):834-840. doi:10.1177/000348940111000906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11558759/pubmed" id="11558759" target="_blank">11558759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760444">
<a name="16760444"></a>Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, “Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,” <i>N Engl J Med</i>, 2006, 354(23):2443-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/16760444/pubmed" id="16760444" target="_blank">16760444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428706">
<a name="16428706"></a>Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. <i>Chest</i>. 2006;129(1 Suppl):169S-173S. doi:10.1378/chest.129.1_suppl.169S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/16428706/pubmed" id="16428706" target="_blank">16428706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23551721">
<a name="23551721"></a>Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. <i>J Clin Hypertens (Greenwich)</i>. 2013;15(4):230-233. doi:10.1111/jch.12063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/23551721/pubmed" id="23551721" target="_blank">23551721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20093343">
<a name="20093343"></a>Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. <i>Clin J Am Soc Nephrol</i>. 2010;5(4):703-708. doi:10.2215/CJN.07371009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20093343/pubmed" id="20093343" target="_blank">20093343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36481180">
<a name="36481180"></a>Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. <i>Kidney Int</i>. 2023;103(2):264-281. doi:10.1016/j.kint.2022.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/36481180/pubmed" id="36481180" target="_blank">36481180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070666">
<a name="25070666"></a>Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2014;130(19):1749-1767. doi: 10.1161/CIR.0000000000000095.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25070666/pubmed" id="25070666" target="_blank">25070666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12598508">
<a name="12598508"></a>Filler G, Wong H, Condello AS, et al. Early dialysis in a neonate with intrauterine lisinopril exposure. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2003;88(2):F154-F156. doi:10.1136/fn.88.2.f154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/12598508/pubmed" id="12598508" target="_blank">12598508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17137886">
<a name="17137886"></a>Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. <i>J Pediatr</i>. 2006;149(6):746-754. Review.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/17137886/pubmed" id="17137886" target="_blank">17137886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3);e20171904. doi:10.1542/peds.2017-1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10999979">
<a name="10999979"></a>Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. <i>Arch Intern Med</i>. 2000;160(17):2645-2650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/10999979/pubmed" id="10999979" target="_blank">10999979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27797886">
<a name="27797886"></a>Georgianos PI, Agarwal R. Pharmacotherapy of hypertension in chronic dialysis patients. <i>Clin J Am Soc Nephrol</i>. 2016;11(11):2062-2075. doi:10.2215/CJN.00870116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/27797886/pubmed" id="27797886" target="_blank">27797886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21734640">
<a name="21734640"></a>Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. <i>Kidney Int</i>. 2011;80(8):868-878. doi: 10.1038/ki.2011.195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/21734640/pubmed" id="21734640" target="_blank">21734640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7910229">
<a name="7910229"></a>GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. <i>Lancet</i>. 1994;343(8906):1115-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/7910229/pubmed" id="7910229" target="_blank">7910229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11518790">
<a name="11518790"></a>Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis.<i> J Am Soc Nephrol.</i> 2001;12(9):1958-1964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11518790/pubmed" id="11518790" target="_blank">11518790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28084903">
<a name="28084903"></a>Hallberg P, Persson M, Axelsson T, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. <i>Pharmacogenomics</i>. 2017;18(3):201-213. doi:10.2217/pgs-2016-0184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/28084903/pubmed" id="28084903" target="_blank">28084903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17216247">
<a name="17216247"></a>Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. <i>Pediatr Nephrol</i>. 2007; 22(5):695-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/17216247/pubmed" id="17216247" target="_blank">17216247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1616218">
<a name="1616218"></a>Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. <i>Ann Intern Med</i>. 1992;117(3):234-242. doi:10.7326/0003-4819-117-3-234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/1616218/pubmed" id="1616218" target="_blank">1616218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30766160">
<a name="30766160"></a>Jenks CM, Newkirk AJ. Hyponatremia secondary to lisinopril in a veteran patient. <i>Fed Pract</i>. 2016;33(2):30-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/30766160/pubmed" id="30766160" target="_blank">30766160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32782860">
<a name="32782860"></a>Jiang Y, Cai W, Masquelin ME, Gordon K. An unexpected case of lisinopril-associated severe hyponatremia. <i>Cureus</i>. 2020;12(7):e9039. doi:10.7759/cureus.9039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/32782860/pubmed" id="32782860" target="_blank">32782860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Internation Supplements. 2012;2(5).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021b;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 10: Immunoglobulin A nephropathy. <i>Kidney Int Suppl (2011).</i> 2012;2(2):209-217. doi:10.1038/kisup.2012.23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int.</i> 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl (2013).</i> 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1855477">
<a name="1855477"></a>Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. <i>Endocrinology</i>. 1991;129(2):823-831. doi:10.1210/endo-129-2-823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/1855477/pubmed" id="1855477" target="_blank">1855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16043683">
<a name="16043683"></a>Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. <i>Arch Intern Med</i>. 2005;165(14):1637-1642. doi:10.1001/archinte.165.14.1637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/16043683/pubmed" id="16043683" target="_blank">16043683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29884969">
<a name="29884969"></a>Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. <i>Curr Hypertens Rep</i>. 2018;20(7):55. doi:10.1007/s11906-018-0859-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/29884969/pubmed" id="29884969" target="_blank">29884969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2172073">
<a name="2172073"></a>Larrey D, Babany G, Bernuau J, et al. Fulminant hepatitis after lisinopril administration. <i>Gastroenterology</i>. 1990;99(6):1832-1833. doi:10.1016/0016-5085(90)90496-n<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/2172073/pubmed" id="2172073" target="_blank">2172073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Lisinopril tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lyden.2003">
<a name="Lyden.2003"></a>Lyden P. May 13 highlights. <i>Neurology</i>. 2003;60(9):1403-1405. https://n.neurology.org/content/neurology/60/9/1403.full.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8938674">
<a name="8938674"></a>MacGregor MS, Rowe PA, Watson MA, Rodger RS, Junor BJ, Briggs JD. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. <i>Nephron</i>. 1996;74(3):517-521. doi: 10.1159/000189445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8938674/pubmed" id="8938674" target="_blank">8938674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2">
<a name="Mann.2"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32496628">
<a name="32496628"></a>Maroteau C, Siddiqui MK, Veluchamy A, et al. Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema. <i>Clin Pharmacol Ther</i>. 2020;108(6):1195-1202. doi:10.1002/cpt.1927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/32496628/pubmed" id="32496628" target="_blank">32496628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.1">
<a name="Meyer.1"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413488">
<a name="18413488"></a>Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. <i>Hypertension</i>. 2008;51(6):1624-1630. doi:10.1161/HYPERTENSIONAHA.108.110270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/18413488/pubmed" id="18413488" target="_blank">18413488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31835086">
<a name="31835086"></a>Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. <i>Int Immunopharmacol</i>. 2020;78:106081. doi:10.1016/j.intimp.2019.106081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31835086/pubmed" id="31835086" target="_blank">31835086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15482412">
<a name="15482412"></a>Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. <i>J Eval Clin Pract</i>. 2004;10(4):499-509. doi:10.1111/j.1365-2753.2003.00484.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/15482412/pubmed" id="15482412" target="_blank">15482412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30672376">
<a name="30672376"></a>Mu G, Xiang Q, Zhou S, et al. Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis. <i>Pharmacogenomics</i>. 2019;20(3):189-212. doi:10.2217/pgs-2018-0157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/30672376/pubmed" id="30672376" target="_blank">30672376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32397904">
<a name="32397904"></a>Mu G, Xiang Q, Zhang Z, et al. PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study. <i>Pharmacogenomics</i>. 2020;21(9):601-614. doi:10.2217/pgs-2019-0167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/32397904/pubmed" id="32397904" target="_blank">32397904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18825420">
<a name="18825420"></a>Nakanishi K, Iijima K, Ishikura K, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. <i>Pediatr Nephrol</i>. 2009;24(4):845-849. doi:10.1007/s00467-008-1006-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/18825420/pubmed" id="18825420" target="_blank">18825420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. <i>Clinical Practice Guidelines</i>. 2011. National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation. </i>2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32291375">
<a name="32291375"></a>Oktaviono YH, Kusumawardhani N. Hyperkalemia associated with angiotensin converting Enzyme inhibitor or angiotensin receptor blockers in chronic kidney disease. <i>Acta Med Indones</i>. 2020;52(1):74-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/32291375/pubmed" id="32291375" target="_blank">32291375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7848615">
<a name="7848615"></a>Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. <i>Am J Hypertens</i>. 1994;7(11):1012-1015. doi:10.1093/ajh/7.11.1012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/7848615/pubmed" id="7848615" target="_blank">7848615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8862965">
<a name="8862965"></a>Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. <i>Drug Saf</i>. 1996;15(1):72-78. doi:10.2165/00002018-199615010-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8862965/pubmed" id="8862965" target="_blank">8862965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27490717">
<a name="27490717"></a>Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. <i>Pharmacol Ther</i>. 2016;167:132-145. doi:10.1016/j.pharmthera.2016.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/27490717/pubmed" id="27490717" target="_blank">27490717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis.<i> Can J Neurol Sci</i>. 2012;39(2)(suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Whitehouse.1">
<a name="Whitehouse.1"></a>Prinivil (lisinopril) [prescribing information]. Whitehouse Station, NJ: Merck and Co Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Prinivil (lisinopril) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azurity.1">
<a name="Azurity.1"></a>Qbrelis (lisinopril) [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azurity.2">
<a name="Azurity.2"></a>Qbrelis (lisinopril) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2188439">
<a name="2188439"></a>Raia JJ Jr, Barone JA, Byerly WG, et al, “Angiotensin-Converting Enzymes Inhibitors: A Comparative Review,” <i>DICP</i>, 1990, 24(5):506-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/2188439/pubmed" id="2188439" target="_blank">2188439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9437375">
<a name="9437375"></a>Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. <i>Arch Intern Med</i>. 1998;158(1):26-32. doi:10.1001/archinte.158.1.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/9437375/pubmed" id="9437375" target="_blank">9437375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reeder.1">
<a name="Reeder.1"></a>Reeder GS, Kennedy HL. Overview of the non-acute management of ST elevation myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 28, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22754420">
<a name="22754420"></a>Rosenbaum AJ, Luciano JA, Marburger R, Hume E. Acute kidney injury in the setting of knee arthroplasty: a case report and discussion investigating Angiotensin-converting enzyme inhibitors as the culprit. <i>HSS J</i>. 2011;7(2):183-186. doi:10.1007/s11420-010-9189-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22754420/pubmed" id="22754420" target="_blank">22754420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hyperten</i>s. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992489">
<a name="25992489"></a>Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. <i>Clin Exp Hypertens</i>. 2015;37(7):563-568. doi:10.3109/10641963.2015.1026040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25992489/pubmed" id="25992489" target="_blank">25992489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25569668">
<a name="25569668"></a>Sato R, Ikuma M, Takagi K, et al. Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in Japan. <i>Medicine (Baltimore)</i>. 2015;94(1):e386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/25569668/pubmed" id="25569668" target="_blank">25569668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8382847">
<a name="8382847"></a>Sauron C, Berthoux P, Berthoux F, et al. New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. <i>Transplant Proc</i>. 1993;25(1, pt 2):1032-1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8382847/pubmed" id="8382847" target="_blank">8382847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11141144">
<a name="11141144"></a>Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. <i>BMJ</i>. 2001;322(7277):19-22. doi:10.1136/bmj.322.7277.19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/11141144/pubmed" id="11141144" target="_blank">11141144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7519541">
<a name="7519541"></a>Schratzlseer G, Lipp T, Riess G, Antoni D, Delius W. Schwere Panzytopenie im hohen Lebensalter nach zwölfmonatiger ACE-Hemmer-Therapie [Severe pancytopenia in old age after 12-month ACE inhibitor therapy]. <i>Dtsch Med Wochenschr</i>. 1994;119(30):1029-1033. doi:10.1055/s-2008-1058798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/7519541/pubmed" id="7519541" target="_blank">7519541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17539955">
<a name="17539955"></a>Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis--an open label study. <i>Eur J Neurol.</i> 2007;14(6):701-703. doi:10.1111/j.1468-1331.2007.01764.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/17539955/pubmed" id="17539955" target="_blank">17539955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31888533">
<a name="31888533"></a>Scott J, Jones T, Redaniel MT, May MT, Ben-Shlomo Y, Caskey F. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink. <i>BMC Nephrol</i>. 2019;20(1):481. doi:10.1186/s12882-019-1633-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31888533/pubmed" id="31888533" target="_blank">31888533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30363665">
<a name="30363665"></a>Sczepanski M, Bozyk P. Institutional incidence of severe tPA-induced angioedema in ischemic cerebral vascular accidents. <i>Crit Care Res Pract</i>. 2018;2018:9360918. doi:10.1155/2018/9360918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/30363665/pubmed" id="30363665" target="_blank">30363665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singh.2014">
<a name="Singh.2014"></a>Singh G, Kachalia A, Kaur J, Kachalia K, Liu S, Rizzo V. Cholestatic hepatitis: An unusual presentation of lisinopril induced hepatotoxicity. <i>BJMP</i>. 2014;7(3):a721.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2840522">
<a name="2840522"></a>Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. <i>JAMA</i>. 1988;260(7):967-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/2840522/pubmed" id="2840522" target="_blank">2840522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” <i>Circulation</i>, 2011, 124(22):2458-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache.<i> J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vlahakos.1">
<a name="Vlahakos.1"></a>Vlahakos DV, Alasfar S. Kidney transplantation in adults: posttransplant erythrocytosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12631334">
<a name="12631334"></a>Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. <i>Kidney Int.</i> 2003;63(4):1187-1194. doi: 10.1046/j.1523-1755.2003.00850.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/12631334/pubmed" id="12631334" target="_blank">12631334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9530537">
<a name="9530537"></a>Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. <i>Drug Saf</i>. 1998;18(3):171-188. doi:10.2165/00002018-199818030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/9530537/pubmed" id="9530537" target="_blank">9530537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10644922">
<a name="10644922"></a>von Vigier RO, Mozzettini S, Truttmann AC, Meregalli P, Ramelli GP, Bianchetti MG. Cough is common in children prescribed converting enzyme inhibitors. <i>Nephron</i>. 2000;84(1):98. doi:10.1159/000045552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/10644922/pubmed" id="10644922" target="_blank">10644922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8723367">
<a name="8723367"></a>Wang AY, Lai KN, Li PK, Leung CB, Lui SF. Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. <i>Ren Fail</i>. 1996;18(2):293-298. doi:10.3109/08860229609052799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8723367/pubmed" id="8723367" target="_blank">8723367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?. <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20150448">
<a name="20150448"></a>Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clin J Am Soc Nephrol</i>. 2010;5(3):531-548. doi:10.2215/CJN.07821109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20150448/pubmed" id="20150448" target="_blank">20150448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12165228">
<a name="12165228"></a>White KL. Psoriasis and psoriatic arthritis, axial type. <i>Dermatol Online J</i>. 2001;7(2):12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/12165228/pubmed" id="12165228" target="_blank">12165228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22845880">
<a name="22845880"></a>Winnicki W, Prehslauer A, Kletzmayr J, et al. Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. <i>Eur J Clin Invest</i>. 2012;42(10):1087-1093. doi:10.1111/j.1365-2362.2012.02699.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/22845880/pubmed" id="22845880" target="_blank">22845880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625347">
<a name="20625347"></a>Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. <i>Pharmacogenet Genomics</i>. 2010;20(9):532-536. doi:10.1097/FPC.0b013e32833d3acb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20625347/pubmed" id="20625347" target="_blank">20625347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8562296">
<a name="8562296"></a>Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. <i>Br J Clin Pharmacol</i>. 1995;40(2):141-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8562296/pubmed" id="8562296" target="_blank">8562296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703645">
<a name="8703645"></a>Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. <i>Br J Clin Pharmacol</i>. 1995;40(5):423-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/8703645/pubmed" id="8703645" target="_blank">8703645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378520">
<a name="18378520"></a>Yusuf S, Teo KK, ONTARGET Investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med</i>. 2008;358(15):1547-1559. doi:10.1056/NEJMoa0801317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/18378520/pubmed" id="18378520" target="_blank">18378520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689125">
<a name="20689125"></a>Zalawadiya SK, Sethi S, Loe S, et al. Unique case of presumed lisinopril-induced hepatotoxicity. <i>Am J Health Syst Pharm</i>. 2010;67(16):1354-1356. doi:10.2146/ajhp100083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lisinopril-drug-information/abstract-text/20689125/pubmed" id="20689125" target="_blank">20689125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Almatica.1">
<a name="Almatica.1"></a>Zestril (lisinopril) [prescribing information]. Morristown, NJ: Almatica Pharma LLC; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Searchlight.1">
<a name="Searchlight.1"></a>Zestril (lisinopril) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; July 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9565 Version 815.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
